Raymond James Financial’s Pyxis Oncology PYXS Stock Holding History

Raymond James Financial’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3,231	Closed	-$3.55K	–	6323
2025 Q2	$3.55K	Buy	+3,231	New	+$3.64K	﹤0.01%	6270

Other funds holding PYXS

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Raymond James Financial's PYXS Position: Q3 2025 in Review

Raymond James Financial sold out of Pyxis Oncology (PYXS) in Q3 2025, closing a stake of 3,231 shares — an estimated $3.55K sold.

Raymond James Financial first reported a position in PYXS in Q2 2025 and held it in 1 quarter. The position peaked at $3.55K in Q2 2025. 73 funds tracked by Wall St. Rank hold PYXS as of Q3 2025.

Raymond James Financial reported no remaining Pyxis Oncology position as of Q3 2025 after selling out during the quarter.
Raymond James Financial sold 3,231 Pyxis Oncology shares in Q3 2025, an estimated $3.55K.
Raymond James Financial first reported a position in Pyxis Oncology in Q2 2025 and held it in 1 quarter.
Raymond James Financial's Pyxis Oncology position peaked at $3.55K in Q2 2025.
73 funds tracked by Wall St. Rank held Pyxis Oncology as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.